z-logo
open-access-imgOpen Access
Primary malignant lymphoma of the brain: Frequent abnormalities and inactivation of p14 tumor suppressor gene
Author(s) -
Zhang ShuJing,
Endo Sumio,
Saito Takafumi,
Kouno Mitsuo,
Kuroiwa Toshihiko,
Washiyama Kazuo,
Kumanishi Toshiro
Publication year - 2005
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2005.00003.x
Subject(s) - exon , biology , missense mutation , southern blot , tumor suppressor gene , microbiology and biotechnology , gene , methylation , mutation , carcinogenesis , lymphoma , cancer research , genetics , immunology
Ten primary central nervous system lymphomas (PCNSL, brain lymphomas) were examined for p14 gene exon 1β deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot‐based methylation assay. In Southern blot analysis, from the signal densities of the hybridized bands and their similarities to those of exons 2 and 3 in our previous quantitative study, we found that exon 1β was homozygously deleted in four cases, hemizygously deleted in five cases and not deleted in one case. Thus, the same deletion patterns covered the entire p14 gene for all cases except for one case, which suggested the hemizygous deletion of exons 1β and 2 and homozygous deletion of exon 3. In addition, although exon 1β mutation is rare in various tumors, we detected a missense mutation (L50R) in one case with a hemizygous deletion. Methylation of the 5′CpG island of the p14 gene was not suggested for any case without homozygous deletion. Our observation of frequent p14 gene abnormalities (90%) and inactivation (40–60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma. ( Cancer Sci 2005; 96: 38 –41)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here